Selegiline reduces daytime sleepiness in patients with Parkinson's disease

Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given selegiline, a selective inhibitor of monoamine oxidase B, experienced an improvement in their daytime somnolence.

• Publication year

  2021

• Venue

  Brain and Behavior

• Publication date

  2021-03-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/brb3.1880PMID 33759401PMCID 8119812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Selegiline reduces daytime sleepiness in patients with Parkinson's disease

  2021cited by this paper
• Excessive Daytime Sleepiness in Parkinson's Disease: Clinical Implications and Management

  2018cited by this paper
• Erratum to: Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study

  2017cited by this paper
• Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease

  2017cited by this paper
• Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study

  2017cited by this paper
• Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study.

  2017cited by this paper
• Insomnia and somnolence in idiopathic RBD: a prospective cohort study

  2017cited by this paper
• Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis.

  2016cited by this paper
• Development of excessive daytime sleepiness in early Parkinson disease

  2015cited by this paper
• Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies

  2015cited by this paper
• International classification of sleep disorders-third edition: highlights and modifications.

  2014cited by this paper
• Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.

  2014cited by this paper
• Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease.

  2014cited by this paper
• Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease

  2012cited by this paper
• Caffeine for treatment of Parkinson disease

  2012cited by this paper
• Observational study of sleep-related disorders in Italian patients with Parkinson’s disease: usefulness of the Italian version of Parkinson’s disease sleep scale

  2012influential reference
• The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease

  2011cited by this paper
• Selegiline and rasagiline: twins or distant cousins?

  2011cited by this paper
• Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease

  2011cited by this paper
• Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial.

  2011cited by this paper
• Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

  2008cited by this paper
• Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.

  2007cited by this paper
• Effects of selegiline on antioxidant systems in the nigrostriatum in rat

  2006cited by this paper
• Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease

  2006cited by this paper
• Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial

  2005cited by this paper
• Excessive daytime sleepiness and subsequent development of Parkinson disease

  2005cited by this paper
• Italian version of the Epworth sleepiness scale: external validity

  2003cited by this paper
• Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.

  2002cited by this paper
• Therapy with l‐deprenyl (selegiline) and relation to abuse liability *

  1994cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper

• Managing sleep issues in Parkinson’s disease: an up-to-date review

  2025cites this paper
• Excessive daytime sleepiness and gait disturbances in patients with Parkinson’s disease

  2025cites this paper
• Experimental models and behavioral parameters for evaluation of Parkinson disease

  2025cites this paper
• The Role of MAO-B Inhibitors in Fatigue in Parkinson’s Disease: A Narrative Review

  2025influential citation
• Treatment of Motor Symptoms of Parkinson's Disease.

  2025cites this paper
• Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review

  2024cites this paper
• Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome

  2024cites this paper
• Early Detection Of Parkinson’s Disease Using Machine And Deep Learning Models

  2024cites this paper
• Sleep disorders and Parkinson’s disease: is there a right direction?

  2024cites this paper
• A Computerized Analysis with Machine Learning Techniques for the Diagnosis of Parkinson’s Disease: Past Studies and Future Perspectives

  2022cites this paper
• A Potential Treatment for Parkinson’s Sleep Disorder: Melatonin

  2022cites this paper
• Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review

  2022cites this paper
• Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

  2022cites this paper
• Excessive Daytime Sleepiness in Parkinson’s Disease

  2022cites this paper
• Effects of repetitive transcranial magnetic stimulation over right dorsolateral prefrontal cortex on excessive daytime sleepiness in patients with Parkinson's disease.

  2022cites this paper
• Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey

  2022cites this paper
• Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future

  2021cites this paper
• Selegiline reduces daytime sleepiness in patients with Parkinson's disease

  2021cites this paper